Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Venture Life Group plc (VLG.L)
Bracknell, GB
Established in Bracknell, UK, in 2005, Venture Life Group plc is an international developer and marketer of diverse health and personal care items. The company's portfolio spans oral care products, dietary supplements, medical devices, dermo-cosmetics, and topical applications, serving a global market across the United Kingdom, various European countries (including the Netherlands, Germany, Italy, and Switzerland), and China. Operating through its distinct Venture Life Brands and Customer Brands divisions, the company offers a comprehensive array of solutions. These include advanced neurology-focused nutritional supplements such as NeuroAge, NeuroAge Sleep, and NeuroAge NRG, designed to enhance alertness, cognitive abilities, and mental acuity. For hair health, Original Bioscalin addresses hair loss, thinning, and baldness. The Myco Clear range provides antifungal nail solutions, comprising a Fungal Nail Solution for treatment and prevention, and a Fungal Nail Cleanser for foot and hand hygiene. In the realm of oral care, UltraDEX is formulated to combat bad breath, while Dently Dual Action is a mouthwash engineered to effectively remove plaque and bacteria. For anal discomfort, Procto-eze plus offers relief for conditions like haemorrhoids and general irritation. Venture Life also features a dedicated women's healthcare line under the vonalei brand, which includes a refreshing gel for bacterial vaginosis, a vaginal cream for atrophy, a soothing cream-gel for candidiasis (thrush), and an intimate cleansing foam. Its dermo-cosmetic selections encompass the Rosa calma brand's Cleansing Foam, Cleansing Cream, and Serum, alongside the Lubatti Classic and Lubatti Anti-age skincare collections. These skincare lines are meticulously crafted to hydrate, nourish, and recondition the skin, helping to minimize the appearance of lines and wrinkles. The company distributes its extensive product offerings through a broad network that includes international partners, pharmacies, and major grocery retailers.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -1.74% | -18.41% | -7.38% | -14.39% | +1.80% | +51.68% | -37.91% | -8.00% | -47.37% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+32.2% ★ Q4'25: -29.2% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+1,848.0% ★ Q4'25: +2,409.1% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+15.0% ★ Q4'25: -4.9% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+3.0% Q4'25: +7.4% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.2% Q4'25: +7.3% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+10.5% Q4'25: -2.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.13× ★ Q4'25: 0.05× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.19M
est: 9.24M (-22.2%)
|
9.08M
est: 9.00M (+0.9%)
|
14.28M
est: 14.30M (-0.1%)
|
16.05M
est: 16.13M (-0.5%)
|
18.77M
est: 18.37M (+2.2%)
|
20.21M
est: 20.18M (+0.2%)
|
30.08M
est: 30.09M (0.0%)
|
32.76M
est: 32.60M (+0.5%)
|
43.98M
est: 44.00M (0.0%)
|
51.41M
est: 51.41M (+0.0%)
|
26.59M
est: 51.80M (-48.7%)
|
35.17M
est: 35.10M (+0.2%)
|
42.60M
42.60M – 42.60M
+21.4% YoY
|
46.50M
46.49M – 46.51M
+9.2% YoY
|
| EBITDA |
-815.0K
est: 1.61M (-150.5%)
|
-713.0K
est: -812.0K (+12.2%)
|
573.0K
est: -1.18M (+148.5%)
|
1.77M
est: -819.1K (+316.1%)
|
2.60M
est: 827.8K (+214.6%)
|
2.80M
est: 1.93M (+44.5%)
|
5.60M
est: 4.21M (+33.1%)
|
5.16M
est: 4.73M (+9.2%)
|
7.61M
est: 7.68M (-0.9%)
|
9.95M
est: 8.55M (+16.4%)
|
4.32M
est: 8.61M (-49.8%)
|
5.08M
est: 5.84M (-12.9%)
|
7.08M
7.08M – 7.08M
+21.4% YoY
|
7.73M
7.73M – 7.73M
+9.2% YoY
|
| EBIT |
-1.46M
est: 621.5K (-335.2%)
|
-1.54M
est: -1.60M (+3.6%)
|
-465.0K
est: -2.66M (+82.5%)
|
581.0K
est: -532.7K (+209.1%)
|
1.22M
est: 655.2K (+86.7%)
|
1.43M
est: 1.16M (+23.1%)
|
3.61M
est: 1.91M (+88.7%)
|
1.46M
est: 2.15M (-32.1%)
|
2.23M
est: 2.96M (-24.8%)
|
3.30M
est: 2.53M (+30.5%)
|
1.52M
est: 2.55M (-40.6%)
|
1.05M
est: 1.73M (-39.5%)
|
2.10M
2.10M – 2.10M
+21.4% YoY
|
2.29M
2.29M – 2.29M
+9.2% YoY
|
| Net Income |
-1.57M
est: -7.90M (+80.1%)
|
-1.76M
est: -1.55M (-13.4%)
|
-1.37M
est: -2.77M (+50.6%)
|
-367.0K
est: -1.57M (+76.6%)
|
236.0K
est: -413.9K (+157.0%)
|
904.0K
est: 260.8K (+246.7%)
|
2.37M
est: 1.35M (+75.0%)
|
2.40M
est: 1.52M (+58.0%)
|
520.0K
est: 4.35M (-88.0%)
|
921.0K
est: 821.2K (+12.2%)
|
-314.0K
est: 6.16M (-105.1%)
|
6.13M
est: 5.32M (+15.1%)
|
7.42M
7.42M – 7.42M
+39.5% YoY
|
8.96M
8.96M – 8.96M
+20.8% YoY
|
| SGA |
3.37M
est: 2.14M (+57.6%)
|
3.44M
est: 3.34M (+3.2%)
|
4.38M
est: 6.06M (-27.7%)
|
4.38M
est: 5.70M (-23.3%)
|
4.54M
est: 6.12M (-25.9%)
|
5.12M
est: 4.59M (+11.6%)
|
7.89M
est: 7.66M (+2.9%)
|
8.31M
est: 8.61M (-3.5%)
|
10.75M
est: 10.20M (+5.4%)
|
8.76M
est: 12.36M (-29.1%)
|
6.07M
est: 12.46M (-51.3%)
|
10.75M
est: 8.44M (+27.4%)
|
10.24M
10.24M – 10.24M
+21.4% YoY
|
11.18M
11.18M – 11.18M
+9.2% YoY
|
| EPS |
-0.06
est: -0.06 (+3.7%)
|
-0.05
est: -0.06 (+17.5%)
|
-0.04
est: -0.04 (+1.2%)
|
-0.01
est: -0.02 (+48.6%)
|
0.00
est: 0.01 (-72.5%)
|
0.01
est: 0.02 (-28.6%)
|
0.03
est: 0.04 (-33.1%)
|
0.02
est: 0.03 (-25.4%)
|
0.00
est: 0.03 (-88.1%)
|
0.01
est: 0.01 (+24.5%)
|
0.00
est: 0.04 (-105.7%)
|
0.05
est: 0.04 (+26.1%)
|
0.05
0.05 – 0.05
+39.5% YoY
|
0.06
0.06 – 0.06
+20.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-26 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-15 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeremy Anthony Philip Randall | Co-Founder, Chief Executive Officer & Executive Director | 393.0K | male |
| Daniel James Wells | Chief Financial Officer & Director | 244.7K | male |
| Ennio Schiro | Head of ESG Strategy | — | male |
| Katherine Louise Bache | Chief Marketing & Innovation Officer and Director | — | female |
| Louise McCarthy | Company Secretary | — | — |
| Matt Jeffs | Head of M&A | — | male |
| Ben Colman | Director of Corporate Development | — | — |
| Peter Jackson | Chief Digital & Technology Officer | — | male |
| Domenico Barbaro | Head of Procurement | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VLG.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
